T2 Biosystems expands its leadership in direct-from-whole-blood detection of sepsis-causing pathogens

T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, has announced plans to license its proprietary technology to expand its leadership in direct-from-whole-blood detection of sepsis-causing pathogens. T2 Biosystems’ proprietary technology is a key component of its FDA-cleared products, including the first and only products able to detect sepsis-causing pathogens directly from whole blood.

T2 Biosystems’ expanded business model is intended to generate non-dilutive capital through licensing agreements that provide access to the company’s patented direct-from-whole-blood technology, create a new royalty revenue stream, and accelerate the broad adoption of direct-from-whole-blood diagnostics to detect sepsis-causing pathogens and antibiotic resistance.

The company’s FDA-cleared products are powered by its proprietary sample processing and magnetic resonance (T2MR^®) detection. Through its research and development efforts, T2 Biosystems has determined that its patented sample processing may be adapted to other detection methods, including fluorescence, potentially enabling other diagnostic platforms to also detect sepsis-causing pathogens and antibiotic resistance directly-from-whole-blood.

Additional revenue streams will allow continued focus on core priorities of accelerating sepsis test sales on the T2Dx instrument and reducing operational costs. Accordingly, the company believes now is the optimal time to license its proprietary technology to accelerate broad adoption of direct-from-whole-blood detection of sepsis-causing pathogens and antibiotic resistance.

“We believe our proprietary technology is a valuable asset and that by licensing our intellectual property to allow other diagnostic firms to integrate our direct-from-whole-blood capabilities into their commercially available instruments, we can generate non-dilutive capital, create a royalty revenue stream, and enable widespread market access to accelerate the broad adoption of blood culture-independent diagnostics,” stated John Sperzel, Chairman and CEO at T2 Biosystems.

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>